872 related articles for article (PubMed ID: 20170948)
1. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
[TBL] [Abstract][Full Text] [Related]
3. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
Weber MA; Jamerson K; Bakris GL; Weir MR; Zappe D; Zhang Y; Dahlof B; Velazquez EJ; Pitt B
Lancet; 2013 Feb; 381(9866):537-45. PubMed ID: 23219284
[TBL] [Abstract][Full Text] [Related]
4. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ;
N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124
[TBL] [Abstract][Full Text] [Related]
5. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
[TBL] [Abstract][Full Text] [Related]
6. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study].
Fan CM; Yan LR; Tao YK; Wang L; Li YQ; Gao MM; Wang YN; Li CX; Wang XW; Lu XL; Pang HM; Li YS
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jan; 39(1):57-60. PubMed ID: 21418799
[TBL] [Abstract][Full Text] [Related]
8. Composite renal endpoints: was ACCOMPLISH accomplished?
Heerspink HL; de Zeeuw D
Lancet; 2010 Apr; 375(9721):1140-2. PubMed ID: 20170949
[No Abstract] [Full Text] [Related]
9. Renal outcomes in hypertensive Black patients at high cardiovascular risk.
Weir MR; Bakris GL; Weber MA; Dahlof B; Devereux RB; Kjeldsen SE; Pitt B; Wright JT; Kelly RY; Hua TA; Hester RA; Velazquez E; Jamerson KA
Kidney Int; 2012 Mar; 81(6):568-76. PubMed ID: 22189843
[TBL] [Abstract][Full Text] [Related]
10. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.
Bakris G; Briasoulis A; Dahlof B; Jamerson K; Weber MA; Kelly RY; Hester A; Hua T; Zappe D; Pitt B;
Am J Cardiol; 2013 Jul; 112(2):255-9. PubMed ID: 23582626
[TBL] [Abstract][Full Text] [Related]
11. Renoprotective effects of benazepril: current perspective.
Stompór T; Napora M; Olszewski A
Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):663-73. PubMed ID: 21714597
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events during differing hypertension therapies in patients with diabetes.
Weber MA; Bakris GL; Jamerson K; Weir M; Kjeldsen SE; Devereux RB; Velazquez EJ; Dahlöf B; Kelly RY; Hua TA; Hester A; Pitt B;
J Am Coll Cardiol; 2010 Jun; 56(1):77-85. PubMed ID: 20620720
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure in renal disease: how to accomplish the goal?
Robles NR; Hernandez-Gallego R
Cardiovasc Ther; 2012 Aug; 30(4):193-8. PubMed ID: 22759229
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension.
Reichek N; Devereux RB; Rocha RA; Hilkert R; Hall D; Purkayastha D; Pitt B
Hypertension; 2009 Oct; 54(4):731-7. PubMed ID: 19687350
[TBL] [Abstract][Full Text] [Related]
17. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study.
Kjeldsen SE; Jamerson KA; Bakris GL; Pitt B; Dahlöf B; Velazquez EJ; Hua TA; Kelly RY; Zappe D; Hester A; Tuomilehto J; Ostergren J; Ibsen H; Weber M;
Blood Press; 2012 Apr; 21(2):82-7. PubMed ID: 21830844
[TBL] [Abstract][Full Text] [Related]
18. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
[TBL] [Abstract][Full Text] [Related]
19. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
[TBL] [Abstract][Full Text] [Related]
20. The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies.
Weder AB
Expert Opin Pharmacother; 2005 Feb; 6(2):275-81. PubMed ID: 15757423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
